title: Recombinant BCG as a vaccine vehicle to protect against tuberculosis.
abstract: Mycobacterium bovis Bacille Calmette Guérin (BCG) was first administered to humans in 1921 and has subsequently been delivered to an estimated 3 billion individuals, with a low incidence of serious complications. The vaccine is immunogenic and is stable and cheap to produce. Additionally, the vaccine can be engineered to express foreign molecules in a functional form, and this has driven the development of BCG as a recombinant vector to protect against infectious diseases and malignancies such as cancer. However, it is now clear that the existing BCG vaccine has proved insufficient to control the spread of tuberculosis, and a major focus of tuberculosis vaccine development programs is the construction and testing of modified forms of BCG. This review summarizes the strategies employed to develop recombinant forms of BCG and describes the potential of these vaccines to stimulate protective immunity and protect against Mycobacterium tuberculosis infection.
authors.affiliation: Discipline of Infectious Diseases and Immunology, Blackburn Building, University of Sydney, NSW Australia. j.triccas@usyd.edu.au
authors.forename: James A
authors.initials: JA
authors.lastname: Triccas
mesh_terms: D000818:Animals; D001500:BCG Vaccine / Q000235:genetics / Q000276:immunology*; D006801:Humans; D009163:Mycobacterium bovis / Q000235:genetics / Q000276:immunology*; D009169:Mycobacterium tuberculosis / Q000276:immunology / Q000502:physiology*; D014376:Tuberculosis / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology
chemical_list: D001500:BCG Vaccine; D014614:Vaccines, Synthetic